These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21756013)

  • 1. Identifying favorable-value cardiovascular health services.
    Braithwaite RS; Mentor SM
    Am J Manag Care; 2011 Jun; 17(6):431-8. PubMed ID: 21756013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-value services in value-based insurance design.
    Neumann PJ; Auerbach HR; Cohen JT; Greenberg D
    Am J Manag Care; 2010 Apr; 16(4):280-6. PubMed ID: 20394464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention.
    Hanley D; Gorelick PB; Elliott WJ; Broder MS; Saver JL; Kidwell CS; Fagan SC; Wilson A; Lennihan L; Schwer WA; Rubenstein LZ; Crowell RM; Haines SJ; Lopez CC; Zorowitz R; Dubois RW
    J Stroke Cerebrovasc Dis; 2004; 13(5):196-207. PubMed ID: 17903976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
    Antioch KM; Jennings G; Botti M; Chapman R; Wulfsohn V
    Eur J Health Econ; 2002; 3(1):26-39. PubMed ID: 15609115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
    Pignone M; Earnshaw S; Pletcher MJ; Tice JA
    Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association.
    Weintraub WS; Daniels SR; Burke LE; Franklin BA; Goff DC; Hayman LL; Lloyd-Jones D; Pandey DK; Sanchez EJ; Schram AP; Whitsel LP; ; ; ; ; ; ; ;
    Circulation; 2011 Aug; 124(8):967-90. PubMed ID: 21788592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of evidence-based therapy for the prevention of cardiovascular events among older people.
    Castelino RL; Chen TF; Guddattu V; Bajorek BV
    Eval Health Prof; 2010 Sep; 33(3):276-301. PubMed ID: 20801973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.